CLINICAL TRIAL: A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZA

临床试验：开放标签 efavirenz 或 ataza 的 IIIB 期随机试验

• 批准号: 8174517
• 负责人: ERIC S DAAR
• 金额: $ 17.56万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174517
• 关键词: Anti-HIV Agents; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Drug Combinations; Funding; Grant; HIV; Institution; Lamivudine; Phase; Research; Research Personnel; Resources; Ritonavir; Safety; Source; Tenofovir; United States Food and Drug Administration; United States National Institutes of Health; abacavir; efavirenz; emtricitabine; open label; randomized trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research is to compare the safety and efficacy and tolerability of different combinations of anti-HIV drugs. All the anti-HIV drugs that are being used in this study are approved by the U.S. Food and Drug Administration (FDA) for treating HIV. The following drug combinations will be used in this study: ¿?¿Efavirenz (EFV) with emtricitabine (FTC) and tenofovir (TDF) ¿?¿EFV with abacavir (ABC) and lamivudine (3TC) ¿?¿Atazanavir (ATV) with ritonavir (RTV) and FTC/TDF ¿?¿ATV with RTV and ABC/3TC

该副本是使用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这是调查员的机构。 这项研究的目的是比较抗HIV药物的不同组合的安全性，效率和耐受性。本研究中使用的所有抗HIV药物均由美国食品药物管理局（FDA）批准治疗HIV。这项研究将使用以下药物组合： efavirenz（EFV）与Emtricitabine（FTC）和Tenofovir（TDF） 与Abcavir（ABC）和Lamivudine（3TC）一起 与Ritonavir（RTV）和FTC/TDF的Atazanavir（ATV） 与RTV和ABC/3TC的ATV